It is well established that KRAS-mutated NSCLC cells display a distinct metabolic profile [29,30] and that KRAS mutations lead to the activation of the MAPK and PI3K/Akt7/mTOR pathways [31]. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.